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Abstract
Introduction: Mesenchymal stem cells (MSCs) can protect bone marrow transplantation (BMT) recipients from
the lethal acute graft-versus-host disease (aGVHD) development. However, the mechanisms underlying the
anti-inflammatory properties of MSCs in aGVHD remain to be elucidated. The immunoregulatory properties
of MSCs are mediated by their production of anti-inflammatory molecules, including IL-10 and TGF-β. On the
other hand, MSCs can also produce proinflammatory cytokines during their normal growth, such as IL-1β and
IL-6. These opposite actions may limit their therapeutic application in aGVHD. Therefore, optimization of the
functional properties of MSCs can increase their benefits.
Methods: The expressions of mRNA and protein were analyzed by real-time PCR and western blotting, respectively.
Expression of MSC markers was assessed by flow cytometry. An animal model of aGVHD was established by
transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. The
recipient mice were divided into the control group and the therapy [adipose tissue-derived human MSCs (Ad-hMSCs)
or rapamycin-treated Ad-hMSCs] groups. The survival, body weight and clinical score of aGVHD in transplanted mice
were monitored.
Results: Rapamycin pre-treatment of Ad-hMSCs increased mRNA synthesis of IL-10, indoleamine 2,3-dioxygenase,
and TGF-β compared with untreated Ad-hMSCs. Rapamycin-treated Ad-hMSCs suppressed clonal expansion
of interleukin-17-producing CD4+ T (Th17) cells more effectively than untreated cells. mRNA expression of
autophagy markers such as ATG5, LC3A and LC3B was significantly increased in the rapamycin-treated Ad-hMSCs
compared with untreated Ad-hMSCs. Transmission electron microscopy revealed that Ad-hMSCs exposure to
rapamycin resulted in the appearance of autophagic vacuoles. Interestingly, in vitro migration efficiency of
rapamycin-treated Ad-hMSCs toward the CD4+ T cells was increased significantly compared with the untreated
cells. And, these effects were associated with autophagy induction capacity of rapamycin. In vivo, the inhibiting
properties of MSCs on the clinical severities of aGVHD were greater in the mice receiving rapamycin-treated
Ad-hMSCs compared with untreated Ad-hMSCs. The beneficial effects of rapamycin treatment in Ad-hMSCs
shown in vivo were associated with a reduction of Th17 cells and an increase in regulatory T cells.
Conclusions: Rapamycin can optimize the immunomodulatory potential of Ad-hMSCs, suggesting a promising
strategy of MSC use in aGVHD treatment.
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Introduction
Allogeneic bone marrow transplantation (BMT) has been
used to treat malignant and nonmalignant hematological
diseases. Despite improvements in conditioning regimens
and graft-versus-host disease (GVHD) prophylaxis, the
development of acute graft-versus-host disease (aGVHD)
remains a lethal and significant complication in allogeneic
BMT recipients, limiting the application and efficacy of
allogeneic BMT [1]. Indeed, GVHD develops in ap-
proximately 40–60 % of recipients [2]. Although the
pathophysiology of aGVHD is not yet understood fully,
immunobiological research has shown GVHD to be a
complex inflammatory process, arising due to activation
and expansion of donor T cells and the production of
proinflammatory cytokines and chemokines, which in-
crease the expression of key receptors on host antigen-
presenting cells (APCs), thereby enhancing cross-
presentation of polypeptide proteins to the donor im-
mune cells [3].
Based on their immunoregulatory properties, which
have been established by pre-clinical studies [4, 5] as well
as by several clinical studies [6, 7], mesenchymal stem
cells (MSCs) are being widely studied as a promising plat-
form for cell-based therapy to prevent or treat aGVHD.
MSCs can decrease GVHD when co-transplanted with
hematopoietic stem cells [8]. Previous case reports dem-
onstrated that grade IV therapy-resistant aGVHDs involv-
ing the gut and liver were rapidly improved after infusion
of bone marrow-derived MSCs (BM-MSCs) that were
isolated from the haploidentical donor, suggesting the
therapeutic potential of third party MSCs [9]. Within the
context of an adaptive immune system, BM-MSCs can
suppress alloreactive T-cell proliferation via contact-
dependent mechanisms and production of soluble fac-
tors, such as IL-10 [10]. MSCs are present in various
tissues including bone marrow, peripheral blood, um-
bilical cord blood, and adipose tissues and possess intrin-
sic immunoregulatory properties that modulate innate
and adaptive immune systems [11–14]. When compared
with BM-MSCs, adipose tissue-derived human MSCs
(Ad-hMSCs) might serve as an alternative with some ad-
vantages; adipose tissue can be obtained in a minimally
invasive manner, such as lipectomy or liposuction. In
addition, previous in vitro studies have established that
Ad-hMSCs also have similar or even higher immunoregu-
latory capacity, when compared with BM-MSCs [15].
Apart from the immunosuppressive activity of MSCs,
the cells were shown to secrete various growth factors,
such as vascular endothelial growth factor (VEGF) [16]
and proinflammatory cytokines, such as IL-6 [17]. Serum
level of VEGF in recipients was suggested as a predictor
for the emergence of GVHD, suggesting the potential as
a principal factor regulating immune reactions associ-
ated with acute and/or chronic GVHD [18]. IL-6 has
recently been proposed as a key mediator in the patho-
genesis of GVHD in an experimental model [19, 20].
Thus, the growth factor and inflammatory cytokines
secreted by MSCs might raise doubts about the clinical
application of MSCs in human GVHD.
Rapamycin was used as an immunosuppressive agent
for the prevention of acute rejection in renal transplant-
ation [21]. Despite wise use of the drug, rapamycin has
adverse effects, including a toxic effect on pancreatic β-
cells [22], dyslipidemia [23], and pulmonary toxicity [24],
thereby limiting the use of the drug in organ transplant
recipients. Interestingly, rapamycin acts by binding to the
mTOR FK506 binding protein complex leading to inhib-
ition of mTOR protein kinase activity. Once mTORC1 is
inactive, autophagy is initiated, in part through phosphor-
ylation of Beclin-1, leading to maturation of the autopha-
gosome from the endoplasmic reticulum [25]. Several
recent studies have revealed that autophagy induction in
MSCs can protect these cells from undergoing apoptosis,
leading to enhanced MSC survival [26]. Several recent
studies have suggested that the management of autoph-
agy in MSCs could optimize their clinical applications
[27, 28]; however, whether autophagy induction in
MSCs influences GVHD prevention is unclear. In this
study, we demonstrated that autophagy induction in
adipose tissue-derived human MSCs (Ad-hMSCs) by
rapamycin treatment enhanced their immunoregulatory
properties and reciprocally inhibited the production of
proinflammatory cytokines. Interestingly, the migration
capability of Ad-hMSCs was significantly enhanced by
rapamycin treatment, and these effects were dependent on
autophagy induction. In vivo, rapamycin-treated Ad-
hMSCs showed more potent inhibition of aGVHD devel-
opment, which was associated with a decrease in Th17 cell
populations. Our findings suggest a role for rapamycin-
mediated autophagy induction as an innovative strategy to




Ad-hMSCs were obtained by simple liposuction from
abdominal subcutaneous fat with informed consent as
approved by the Institutional Review Board of Bucheon
St. Mary’s Hospital. The procedures for the use of Ad-
hMSCs for experimental studies were approved by the In-
stitutional Review Board of Bucheon St. Mary’s Hospital.
All experiments were carried out in compliance with the
Helsinki Declaration. In addition, all animal experimenta-
tion was carried out in strict accordance with the guide-
lines of the Animal Care and Use Committee of The
Catholic University of Korea. The protocol was approved
by the Animal Research Ethics Committee of the Catholic
University of Korea (permit number: 2012-0155-01),
Kim et al. Stem Cell Research & Therapy  (2015) 6:202 Page 2 of 15
which conformed to all US National Institutes of Health
guidelines.
Culture of human adipose tissue-derived mesenchymal
stem cells
Subcutaneous fat was digested with RTase (4 ml/1 g fat;
K-STEMCELL Co. Ltd., Seoul, Korea) for 60 min at 37 °C.
The digested tissues were filtered through a 100-μm nylon
sieve to remove cellular debris. The tissues were then cen-
trifuged at 470 g for 5 min to obtain a pellet. The pellet
was resuspended in RCME cell attachment medium (K-
STEMCELL Co. Ltd.) and cultured overnight at 37 °C
in a humidified atmosphere containing 5 % CO2. After
24 h, non-adherent cells were removed and washed
with phosphate buffered saline (PBS). The cell medium
was changed to RKCM cell growth medium (K-STEM-
CELL Co. Ltd.) containing 5 % fetal bovine serum (FBS:
Invitrogen, Carlsbad, CA, USA). The cells were main-
tained for four days until confluent (passage zero).
When the cells reached 90 % confluency, they were sub-
cultured and expanded in RKCM for two or three pas-
sages, at which point they were used for the experiments.
Animals
Female BALB/c (B/c, H-2kd) and C57BL/6 (B6, H-2kb)
mice, eight to ten weeks of age, were purchased from
the Jackson Laboratory (Bar Harbor, ME, USA) and
maintained under specific pathogen-free conditions in
an animal facility with controlled humidity (55 ± 5 %),
light (12 h/12 h light/dark), and temperature (22 ± 1 °C).
The air in the facility was passed through a HEPA filtra-
tion system designed to exclude bacteria and viruses.
Animals were fed mouse chow with ad libitum access to
tap water.
Real-time polymerase chain reaction
Ad-hMSCs were stimulated with rapamycin (50 nM).
After incubation for 48 h, mRNA was extracted using
RNAzol B (Biotex Laboratories, Houston, TX, USA) ac-
cording to the manufacturer’s instructions. Reverse tran-
scription of 2 μg total mRNA was performed at 42 °C
using the Superscript™ reverse transcription system
(Takara, Shiga, Japan). The polymerase chain reaction
(PCR) was performed in a 20-μl final volume in capillary
tubes in a LightCycler instrument (Roche Diagnostics,
Mannheim, Germany). The reaction mixture contained
2 μl LightCycler FastStart DNA MasterMix for SYBR®
Green I (Roche Diagnostics), 0.5 μM each primer, 4 mM
MgCl2, and 2 μl template DNA. All capillaries were
sealed, centrifuged at 500 × g for 5 s, and then amplified
in the LightCycler, with activation of the polymerase
(95 °C for 10 min), followed by 45 cycles at 95 °C for
10 s, 60 °C (β-actin) or 59 ~ 60 °C (target) for 10 s, and
72 °C for 10 s (Table 1). The temperature transition rate
was 20 °C/s for all steps. The double-stranded PCR
product was measured during the 72 °C extension step
by detection of fluorescence associated with binding of
SYBR Green I to the product. Fluorescence curves were
analyzed using LightCycler software v. 3.0 (Roche Diag-
nostics). The LightCycler was used to quantify the target
mRNA. Relative expression levels were calculated as the
level of target normalized to that of the endogenous
housekeeping gene (β-actin). Melting curve analysis was
performed immediately after amplification under the
following conditions: 0 s (hold time) at 95 °C, 15 s at







IL-6 5′-AATTCGGTACATCCTCG CGG-3′ 5′-GGTTGTTTTCTGCCAGTGCC-3′
HMGB1 5′-GATCCCAATGCACCCAAGAG-3′ 5′-TTCGCAACATCACCAATGA-3′
CCR1 5′-ACCATAGGAGGCCAACCCAAAATA-3′ 5′-TCCATGCTGTGCCAAGAGTCA-3′
CCR2 5′-CTACCTTCCAGTTCCTCATTTT-3′ 5′-ACATTTACAAGTTGCAGTTTTCAG C-3′




CXCR4 5′-ATCCCT GCCCTCCTGCTGACTATTC-3′ 5′-GAGGGCCTTGCGCTTCTGGTG-3′
β - actin 5′-GGACTTCGAGCAAGAGATGG-3′ 5′-TGTGTTGGGGTACAGGTCTTTG-3′
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71 °C, and 0 s (hold time) at 95 °C. The rate of temperature
change was 20 °C/s, except for 0.1 °C/s in the final step.
The melting peak generated represented the amount of spe-
cific product amplified. The crossing point (Cp) was defined
as the maximum of the second derivative from the fluores-
cence curve. Negative controls were also included and
contained all components of the reaction mixture ex-
cept template DNA. All samples were processed in du-
plicate. The following primers were used to amplify
human genes: for IL-10, indoleamine 2,3-dioxygenase
(IDO); TGF-β, high mobility group box 1 (HMGB1),
IL-6, IL-1β, ATG5, LC3A, LC3B, CCR1, CCR2, CCR3,
CCR4, CXCR4, CCR7, CCR9, β-actin primer (Table 1).
Enzyme-linked immunosorbent assay
In brief, a 96-well plate (Nunc) was coated with 4 μg/ml
monoclonal antibodies against IL-10, TGF-beta, IL-6, IL-
1beta and HMGB1 (R & D Systems, BD Biosciences, San
Jose, CA, USA) at 4 °C overnight. After blocking with
phosphate-buffered saline/1 % bovine serum albumin
(BSA)/0.05 % Tween 20 for two hours at room
temperature (22–25 °C), test samples and the standard re-
combinant IL-10, TGF-beta, IL-6, IL-1beta and HMGB1
(R & D Systems, BD Biosciences, San Jose, CA, USA) were
added to the 96-well plate and incubated at room
temperature for two hours. Plates were washed four times
with phosphate-buffered saline/Tween 20, and then incu-
bated with 500 ng/ml biotinylated mouse monoclonal
antibodies against IL-10, TGF-beta, IL-6, IL-1beta, and
HMGB1 (R & D Systems, BD Biosciences, San Jose, CA,
USA) for two hours at room temperature. After washing,
the plates were incubated with streptavidin–alkaline phos-
phate–horseradish peroxidase conjugate (Sigma, Sigma-
Aldrich, St Louis, MO) for two hours, then washed again
and incubated with 1 mg/ml p-nitrophenyl phosphate
(Sigma, Sigma-Aldrich, St Louis, MO) dissolved in
diethanolamine (Sigma, Sigma-Aldrich, St Louis, MO) to
develop the color reaction. The reaction was stopped by
the addition of 1 M NaOH and the optical density of each
well was read at 405 nm. The lower limit of IL-10, TGF-
beta, IL-6, IL-1beta, and HMGB1 detection was 10 pg/ml.
Recombinant human IL-10, TGF-beta, IL-6, IL-1beta, and
HMGB1 diluted in culture medium was used as a calibra-
tion standard, ranging from 10 to 2,000 pg/ml. A standard
curve was drawn by plotting optical density against the
log of the concentration of recombinant cytokines, and
used for determination of IL-10, TGF-beta, IL-6, IL-1beta,
and HMGB1 concentrations in test samples.
Confocal microscopic analysis of IL-10 expression
Immunofluorescence staining was performed on the Ad-
hMSCs for 48 h with or without rapamycin. Ad-hMSCs
were fixed with acetone for 15 min at room temperature
and blocked with 10 % goat serum for 30 min at room
temperature. After incubation with anti-human IL-10
antibody (Santa Cruz Biotechnology, Dallas, TX, USA),
anti-human IDO antibody, and anti–DAPI antibody (R
& D Systems Inc., Minneapolis, MN, USA) overnight at
4 °C, the samples were incubated with fluorescein iso-
thiocyanate–conjugated anti-mouse (Santa Cruz Bio-
technology) and phycoerythrin-conjugated anti-rabbit
IgG secondary antibodies (SouthernBiotech, Birmingham,
AL, USA). The stained sections were visualized under
a Zeiss confocal microscope (LSM 510 META) at
200× and 400× magnification.
Mixed lymphocyte reaction and suppression assay
The mixed lymphocyte reactions (MLR) consisted of
5 × 104 murine CD4+ effector cells stimulated with anti-
CD3 (1 μg/ml), anti-CD28 (1 μg/ml), IL-1β (20 ng/ml),
IL-6 (20 ng/ml), and IL-23 (20 ng/ml) to induce Th17
cells and 5 × 104 irradiated (40 Gy) allogeneic murine
peripheral blood mononuclear cells (PBMCs) in round-
bottomed 96-well plates (Nunc, Roskilde, Denmark) with
PBMC culture medium (PCM) consisting of MEM-a sup-
plemented with 2 mM L-glutamine, 1 % penicillin/strepto-
mycin (P/S) and 10 % heat-inactivated human serum.
Suppression assays were performed to determine the
immunomodulatory capacities of Ad-hMSCs (various
concentrations), Ad-hMSCs (1:10) and rapamycin treated-
Ad-hMSCs (1:10) (alul ratios: indicated cells/effector cells)
in the MLR. CD4+ T cell proliferation was investigated by
adding 3H-thymidine (1 μCi/well; GE Healthcare, Amer-
sham, Buckinghamshire, UK) to the culture medium and
incubating for 8 h. The level of 3H-thymidine incorpor-
ation was measured using a Beckman liquid-scintillation
counter (Beckman Coulter Inc., Brea, CA, USA).
Flow cytometry analysis
Monoclonal antibodies (mAbs) conjugated to fluorescent
dyes targeting human CD13, CD90, CD105, CD29, CD44,
CD11b, CD19, CD31, CD34, CD45, CD25, and HLA-DR
(BD Biosciences, Schwechat, Austria) were used to
characterize the MSCs. Their surfaces were stained using
different combinations of the following mAbs: CD13-PE
(L138, IgG1, κ, Pharmingen, San Diego, CA, USA), CD90-
PE (5E10, IgG1, κ Pharmingen), CD11b-PE (ICRF44, IgG1,
κ, Pharmingen), CD19-PE (HIB19, IgG1, κ, Pharmingen ),
CD34-PE (8G12, IgG1, κ, Pharmingen ), CD34-FITC
(MMA, IgM, Pharmingen ), CD25-APC (PC61, IgG1, λ,
Pharmingen), CD105-APC (RPA-T4, IgG1; BioLegend,
San Diego, CA, USA), CD29-PE (RPA-T8, IgG1, κ; Phar-
mingen), CD44-FITC (HI100, IgG2b, κ; Pharmingen),
CD45-APC (M-A251, IgG1, κ; Pharmingen), and HLA-
DR-PE (G46-6, IgG2a, κ; Pharmingen). For staining intra-
cellularly, the cells were washed, fixed, permeabilized, and
incubated with mAbs against IL-17 (PE, eBio64dec17,
IgG1, κ; eBioscience, San Diego, CA, USA), IFN-γ (FITC,
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4S.B3, IgG1, κ; eBioscience; and PE, B27, IgG1, κ; Phar-
mingen), IL-4 (APC, MP4-25D2, IgG1, κ; eBioscience),
and Foxp3 (FITC, PCH101, IgG2a, κ; eBioscience). Appro-
priate isotype controls were used for gating purposes. Cells
(1 × 105 cells/well) were analyzed using a FACSCalibur
flow cytometer (BD Biosciences). The data were analyzed
using the FlowJo software (Tree Star, Ashland, OR, USA).
Transmission electron microscopy
The cells were harvested, centrifuged (215 × g for
10 min), washed with cold PBS and fixed with 2.5 % glu-
taraldehyde (in 0.2 M sodium cacodylate, pH 7.4). The
samples were then fixed in 1 % OsO4 for 1 h at 4 °C,
dehydrated with increasing concentrations of ethanol,
embedded in spurr resin and sectioned. The ultrathin
sections were stained with uranyl acetate and observed
by transmission electron microscopy (TEM).
Western blot analysis
To examine the effects of rapamycin, Ad-hMSCs were
incubated for 48 h in the presence of rapamycin. The mem-
brane was incubated overnight at 4 °C with primary anti-
bodies against the following: p-mTOR, mTOR, p-Rictor,
Rictor, p-Raptor, Raptor, Beclin1, ATG5, ATG7, LC3 II (all
antibodies were from Cell Signaling Technology Inc., Dan-
vers, MA, USA), and β-actin (Sigma, Sigma-Aldrich, St
Louis, MO). After washing in Tris-buffered saline and
Tween 20 (TTBS), the reactive bands were visualized using
an ECL detection kit and Hyperfilm-ECL reagents
(Amersham Pharmacia Biotech, Little Chalfont, Bucks, UK).
Chemotaxis assay
Cell migration was evaluated using a 48-well modified
Boyden chamber as previously described, with minor
modifications [29]. The polycarbonate filter (12-μm pore
size, CN110416; Neuroprobe, Bethesda, MD, USA) was
pre-coated with fibronectin (5 μg/mL; Sigma); Ad-hMSCs
were resuspended at 5 × 105/mL in the appropriate
medium supplemented with 1 % FBS and seeded in the
upper chamber. CD4+ T cells were able to attract human
MSCs in a classical chemotaxis assay [30]. CD4+ T cells
were used as chemoattractants in the lower compartment.
The chambers were incubated overnight at 37 °C. Results
are expressed as the mean number of net migrated cells
relative to the control cells counted in 10 microscope
fields at high-power magnification (×1,000). Each experi-
ment was performed in triplicate.
The bone marrow transplantation model
The BMT procedure was performed as described previ-
ously [31]. To induce aGVHD, recipients (B/c mice)
were injected intravenously with 5 × 106 donor (B6) bone
marrow cells and 1 × 107 donor splenocytes (as a source
of allogeneic T cells) after lethal irradiation with 800 cGy
[32]. To induce the syngeneic BMT model, recipient B/c
mice were injected intravenously with 5 × 106 donor (B/c)
bone marrow cells and 1 × 107 donor B/c splenocytes after
lethal irradiation with 800 cGy. All experiments were con-
ducted with 12 mice per group. The recipient mice were di-
vided randomly into the control group and the therapy (Ad-
hMSCs or rapamycin-treated Ad-hMSCs) groups. One day
after GVHD induction, the mice were administered saline
(control group), Ad-hMSCs or rapamycin (50 nM)-treated
Ad-hMSCs (1 × 106) via the tail vein. Survival after BMT
was monitored daily, and the day of death was recorded as
that on which the mouse died spontaneously. The extent of
clinical GVHD was assessed twice per day for 30 days after
the BMT, using a scoring system that summed the changes
over five clinical parameters: weight loss, posture, activity,
fur texture, and skin integrity. Animals were sacrificed hu-
manely when they exhibited the euthanasia GVHD criteria
(>20 % weight loss or animals that received a score ≥ 6.5).
Histopathologic analysis of GVHD target organs
The liver and skin tissues isolated from the mice in each
group (control, Ad-hMSC or rapamycin-treated-Ad-
hMSC) were fixed in 10 % formalin, embedded in paraf-
fin, sectioned at 7-μm thickness, deparaffinized using xy-
lene, dehydrated through an alcohol gradient and
stained with hematoxylin and eosin (H & E). GVHD was
scored by two trained pathologists, who were blinded to
the treatment groups, according to previously published
histopathology scoring systems [33].
Staining for confocal microscopic analysis
Spleen tissues were obtained 14 days after BMT, snap-
frozen in liquid nitrogen, and stored at −80 °C. Tissue
cryosections (7-μm thickness) were fixed in 4 % (v/v)
paraformaldehyde and stained using fluorescein isothio-
cyanate (FITC)-, phycoerythrin (PE)-, PerCP-Cy5.5-, or
allophycocyanin (APC)-conjugated monoclonal anti-
bodies to mouse CD4, interferon-gamma (IFN-γ), IL-4,
IL-17, CD25 or Foxp3 (eBioscience). After incubation
overnight at 4 °C, stained sections were visualized by
confocal microscopy (LSM 510 Meta; Zeiss, Göttingen,
Germany). Positive cells were counted manually at a
higher magnification (projected on a screen) by four in-
dividuals, and the results were expressed as means ± SD.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 20 for Windows (IBM Corp., Armonk, NY, USA).
One-way analysis of variance followed by Bonferroni’s
post-hoc test was used to compare the differences be-
tween three or more groups. Comparisons of numerical
data between two groups were performed by Student’s
t-test or a nonparametric Mann–Whitney U test. The
Mann–Whitney U test was used for statistical analysis of
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the clinical scores, while the Mantel-Cox log-rank test
was used to analyze the survival data. The data were
considered significantly different at P < 0.05.
Results
Characterization of rapamycin-treated Ad-hMSCs
Flow cytometry analysis was used to assess whether
rapamycin-treated and untreated Ad-hMSCs showed typ-
ical MSC surface marker profiles. The Ad-hMSCs in both
groups expressed the mesenchymal cell surface markers
CD90, CD13, CD44, CD29, and CD105, and were negative
for CD11b, CD19, CD31, CD34, CD45, and HLA-DR
(Fig. 1a). It was noted that rapamycin-treated Ad-hMSCs
had a very similar surface antigen profile to that of un-
treated Ad-hMSCs. To determine whether rapamycin pre-
treatment in Ad-hMSCs can affect the cells’ capability to
differentiate into multiple cell lineages [34], Ad-hMSCs
were cultured under different conditions: adipogenic
medium (Fig. 1b, upper panel), osteogenic medium (Fig. 1b,
medium channel), or chondrogenic medium (Fig. 1b, lower
panel). The treatment concentration of rapamycin (50 nM)
did not show cellular toxicity, as assessed with MTT assay
(data not shown).
Rapamycin enhanced the immunoregulatory properties of
Ad-hMSCs
To assess whether rapamycin treatment influenced the
immunoregulatory activities in Ad-hMSCs, the mRNA
synthesis of IL-10, IDO, and TGF-β were analyzed by
real-time PCR in Ad-hMSCs with or without rapamycin.
IL-10, IDO, and TGF-β mRNA levels were increased by
rapamycin pretreatment. Also, the concentrations of IL-10
and TGF-β in culture supernatants measured by ELISA
were also increased by rapamycin pretreatment (Fig. 2a).
IL-10 expression was compared between untreated Ad-
hMSCs and rapamycin-treated Ad-hMSCs by confocal mi-
croscopy using triple-immunofluorescence staining. IL-10
(red) and IDO (green) expression was detected abundantly
in the rapamycin-treated Ad-hMSCs, whereas expression
was faint in the Ad-hMSCs without rapamycin treatment
(Fig. 2b). To ascertain whether rapamycin could augment
MSC-induced immunoregulation, rapamycin-treated
Ad-hMSCs were cultured for 48 h in the presence or ab-
sence of rapamycin (Fig. 2c). In vitro co-culture studies
revealed that rapamycin-treated Ad-hMSCs could
suppress clonal expansion of Th17 cells more effectively
than untreated Ad-hMSCs (Fig. 2c). Next, to determine
whether rapamycin regulated the molecules known to
be strongly associated with the development of Th17
cells in Ad-hMSCs, protein and mRNA expression
levels of high-morbidity group box chromosomal pro-
tein 1 (HMGB1) [35], IL-6 [36], and IL-1β [37] were
quantified by sandwich ELISA and real-time PCR, re-
spectively. The results showed significantly suppressed
levels of HMGB1-, IL-6-, and IL-1β mRNA and lower
concentrations of these molecules in the culture super-
natants of rapamycin-treated Ad-hMSCs compared with
untreated Ad-hMSCs (Fig. 2d).
Fig. 1 Surface markers and multilineage differentiation capacity of rapamycin-treated and untreated Ad-hMSCs. a Expression of markers in Ad-hMSCs
was analyzed by flow cytometry. One representative analysis is reported. From left to right: CD90, CD13, CD44, CD29, CD105 (upper row); CD11b, CD19,
CD31, CD34, CD45, HLA-DR (lower row). Red histograms, cells stained with isotype control; blue histogram, cells isolated with specific antibodies. b MSCs
were plated on each differentiation medium. After 1 week (adipogenic differentiation) or 3 weeks (osteoblastogenic and chondrogenic
differentiation), cells were fixed and stained with FABP-4 (top), osteocalcin (middle), or aggrecan (bottom) and visualized by fluorescence
microscopy. Representative images of MSC-induced differentiation into adipogenic, osteogenic, and chondrogenic pathways.. Ad-hMSCs
adipose tissue-derived human MSCs, MSCs mesenchymal stem cells, HLA-DR human leukocyte antigen-DR
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Rapamycin induced autophagy in Ad-hMSCs
To address the question of how rapamycin affected the
immunoregulatory properties of Ad-hMSCs, Ad-hMSCs
were incubated with or without 50 nM rapamycin. In
comparison with untreated cells, rapamycin induced the
formation of small vacuoles inside the cells after 48 h
incubation, consistent with its autophagy-inducing
properties (Fig. 3a). The TEM revealed that Ad-hMSC
exposure to rapamycin resulted in the appearance of
autophagic vacuoles (AV) (Fig. 3a). Beclin 1, ATG5,
ATG7, and LC3 play a central role in autophagy and are
common indicators of the induction of autophagy [38–
40]. Normally, LC3 is present in the cytosol diffusely, but
it is converted from LC3-I (18 kD) to LC3-II (16 kD) upon
autophagy and accumulates on the autophagosome mem-
brane, appearing as dots on the membrane [41, 42]. In this
study, the expression of markers associated with the au-
tophagy pathway in Ad-hMSCs treated with or without
Fig. 2 Immunoregulatory properties of human adipose tissue-derived mesenchymal stem cells (Ad-hMSCs) by rapamycin treatment. a Expression of
IL-10, IDO, and TGF-β was analyzed by real-time PCR and sandwich ELISA in Ad-hMSCs with or without rapamycin. b Immunofluorescence staining of
cultured Ad-hMSCs treated with or without rapamycin with IL-10 (red), IDO (green) and counterstained with DAPI (blue). c T cell proliferation under
Th17 polarizing conditions by rapamycin-treated Ad-hMSCs and untreated Ad-hMSCs. d Expression of HMGB1, IL-6, and IL-1β was analyzed by
real-time PCR and sandwich ELISA in Ad-hMSCs with or without rapamycin. Data are presented as mean ± SD (standard deviation) and represent
three independent experiments (n = 3). *P < 0.05; *** P < 0.001
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rapamycin were analyzed. The expression of mRNA for
ATG5, LC3A, and LC3B was determined using real-time
PCR. The expression of ATG5, LC3A, and LC3B mRNA
was significantly increased in the rapamycin-treated Ad-
hMSCs compared with the untreated Ad-hMSCs (Fig. 3b).
To identify the molecular mechanisms modulated by rapa-
mycin, we investigated whether rapamycin interfered dir-
ectly with mTOR and autophagy signaling. Western
blotting showed that rapamycin not only provoked the ex-
pression of both Beclin 1 and LC3II but also suppressed
the expression of mTOR and mTOR protein complexes
(Rictor and Raptor) (Fig. 3c). These data together proved
that rapamycin treatment in Ad-hMSCs induced autoph-
agy and was associated with inhibition of mTOR/Rictor/
Raptor signaling.
Rapamycin increased the migration capacity and
expression of chemokine receptors in Ad-hMSCs
To evaluate the in vitro migration capacity of rapamycin-
treated Ad-hMSCs, the mRNA expression of chemokine
and chemokine receptors was investigated by real-time
PCR. Ad-hMSCs expressed C-C chemokine receptor type
1 (CCR1), 2 (CCR2), 3 (CCR3), 4 (CCR4), 7 (CCR7), and 9
(CCR9) and C-X-C chemokine receptor type 4 (CXCR4).
The expression of CCR1, CCR2, CCR3, CCR4, CCR7,
CCR9, and CXCR4 mRNA was significantly increased in
the rapamycin-treated Ad-hMSCs compared with the un-
treated Ad-hMSCs (Fig. 4a). As migration of MSCs from
circulation into injured tissues can contribute to their im-
munoregulatory capacities in inflammatory conditions,
we investigated whether their migration efficiency is
Fig. 3 Rapamycin induced autophagy in Ad-hMSCs. a Transmission electron microscopy verified that Ad-hMSCs treated with rapamycin exhibited
numerous cytoplasmic vacuoles, most of which were identified clearly as autophagosomes (with a visible double membrane; red arrow). b mRNA
expression of autophagy markers in Ad-hMSCs treated with or without rapamycin was detected by real-time PCR. c Protein extracts from Ad-hMSCs treated
with or without rapamycin were analyzed by Western blotting using antibodies targeting phosphor-mTOR, mTOR, phosphor-Rictor, Rictor (a novel binding
partner of mTOR), phosphor-Raptor, Raptor, Beclin 1, ATG5, ATG7, and LC3II (left panel). Data in the graphs show the relative intensities of the target proteins
normalized to β-actin; values are presented as means ± SD (n= 3). *P< 0.05; **P< 0.01. Ad-hMSCs adipose tissue-derived human mesenchymal stem cells
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influenced by rapamycin treatment. The in vitro migra-
tion efficiency of rapamycin-treated Ad-hMSCs towards
the CD4+ T cells was increased significantly, with a 2.7-
fold increase compared with the untreated cells
(Fig. 4b). Interestingly, the enhanced migration capacity
seen in the rapamycin-treated Ad-hMSCs was reversed
significantly by bafilomycin (an autophagy inhibitor)
(Fig. 4b). Next, to determine whether the immunoregu-
latory molecules produced by MSCs might be affected
by autophagy, the mRNA level of IL-10, IDO, and TGF-β
was analyzed in rapamycin-treated Ad-hMSCs in the pres-
ence or absence of bafilomycin. The enhanced mRNA
expression of these molecules by rapamycin pretreatment
in Ad-hMSCs was markedly reversed by bafilomycin
(Fig. 4c). Taken together, autophagy-induction properties
of rapamycin in Ad-hMSCs contributed to the enhanced
migration of, and intensified expression of, immunoregu-
latory molecules.
Rapamycin-treated Ad-hMSCs protect mice from aGVHD
after bone marrow transplantation
Because rapamycin significantly enhanced the immuno-
regulatory properties of Ad-hMSCs, we assessed its effects
in vivo using a murine model of aGVHD. Severe aGVHD
occurred in all B/c (H-2kd) recipient mice undergoing
BMT and infusion of donor (B6 mice, H-2kb) splenocytes.
One day after GVHD induction, the mice were adminis-
tered control (saline), Ad-hMSCs, or rapamycin-treated
Ad-hMSCs via the tail vein. Acute GVHD animals trans-
planted with Ad-hMSCs showed reduced weight loss, less
Fig. 4 Migration capacity of Ad-hMSCs is improved by rapamycin (Rapa) via increased expression of chemokine receptors. a mRNA expression of
chemokine receptors in Ad-hMSCs treated with or without rapamycin. Surface expression of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9, and CXCR4 on
Ad-hMSCs was assessed by real-time PCR. Graphs represent the mean chemokine receptor expression of Ad-hMSCs treated with rapamycin (50
nM) compared with the negative control (untreated Ad-hMSCs), and bars represent the standard deviation (SD) from three independent experiments
(n = 3). b Migration assay of Ad-hMSCs in response to CD4+ T cells. Two thousand Ad-hMSCs either untreated (left), treated with rapamycin (middle), or
treated with bafilomycin (Bafilo) and Rapa (right) were placed in the top well of a chemotaxis chamber, with CD4+ T cells present in the bottom well.
After 2 h, the migrating cells were counted. Representative images show the migrating Ad-hMSCs (upper panel). The bar graphs represent the numbers
of migrating Ad-hMSCs as means ± SD (lower panel). c mRNA expression of IL-10 (left), IDO (middle), and TGF-β (right) of Ad-hMSCs was assessed by
real-time PCR. Graphs represent the mean mRNA expression of Ad-hMSCs either untreated, treated with Rapa, or treated with Rapa and Bafilo. Error
bar represents the SD from independent experiments (n = 3). ***P < 0.001. Ad-hMSCs adipose tissue-derived human mesenchymal stem cells
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severe clinical scores of aGVHD, and significantly de-
layed aGVHD-induced lethality compared with the
control aGVHD mice (Fig. 5a). The administration of
rapamycin-treated Ad-hMSCs in the recipient mice
showed less severe clinical scores of aGVHD compared
with untreated-Ad-hMSCs. Furthermore, all the recipi-
ent mice treated with rapamycin-treated Ad-hMSCs
survived for 40 days after BMT (Fig. 5a). Acute GVHD
targets the liver, skin, and intestine. Mice from each
treatment group were sacrificed on day 12 post-BMT
after GVHD-induction. To determine the protective
effects of the rapamycin-treated Ad-hMSCs on the de-
velopment of aGVHD, the tissue pathologies of the
liver, skin, and intestine were evaluated. Recipient mice
administered rapamycin-treated Ad-hMSCs showed
less severe aGVHD pathology scores for the liver, skin,
and intestine, whereas recipient mice administered un-
treated Ad-hMSCs showed moderate aGVHD (Fig. 5b).
Fig. 5 The inhibitory capacity of Ad-hMSCs on aGVHD severity was augmented by rapamycin treatment. a Recipient BALB/c (B/c) mice received
5 × 106 bone marrow cells and 1 × 107 splenocytes from B6 (allogeneic) or B/c mice (syngeneic) after lethal irradiation with 800 cGy. On day 1
post BMT, allogeneic BMT recipient mice received intravenous administration of Ad-hMSCs, rapamycin-treated Ad-hMSCs, or saline (control). Mice
with aGVHD were monitored for weight, clinical signs, and the ability to survive. Combined data from two independent experiments (n = 12 per
group) are shown. Improvements in the clinical aGVHD score after allogeneic BMT was assessed in terms of (reduced) weight loss, posture, activity, fur
texture, and skin integrity. *P < 0.05 (b) Pathology scores (upper panel) and histopathology of the liver, skin, and intestine after BMT (n = 12 per group);
the photographs were taken from one of two independent experiments. The sections were stained with H & E (original magnification × 200). The
upper panel shows the mean scores of the liver, skin, and intestine of four groups. Results are expressed as means ± SD. *P < 0.05; **P < 0.01;
***P < 0.001. Ad-hMSCs adipose tissue-derived human mesenchymal stem cells, aGVHD acute graft-versus-host disease, BMT bone
marrow transplantation
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The histopathologic changes in the nucleus and cyto-
plasm, as well as the extent of infiltrating inflammatory
cells found in the aGVHD target organs were reduced
dramatically in the mice administered rapamycin-
treated Ad-hMSCs (Fig. 5b).
Rapamycin treatment in Ad-hMSCs can modulate the
differentiation of effector T cells and the production of
inflammatory cytokines in vivo
T cells are absolutely essential to cause GVHD [43].
Therefore, to investigate the in vivo mechanism of
rapamycin-treated Ad-hMSCs in the aGVHD murine
model, the numbers of CD4+IFN-γ+, CD4+IL-4+, CD4+IL-
17+, and CD4+CD25+Foxp3+ T cells in spleens isolated
from each group were counted after confocal staining.
The numbers of CD4+IFN-γ+ (mainly Th1) and CD4+IL-
17+ T (mainly Th17) cells in the spleens were lower in the
Ad-hMSC-administered GVHD mice compared with the
control GVHD mice. On the other hand, the numbers
of CD4+IL-4+ (mainly Th2) and CD4+CD25+Foxp3+ T
cells (mainly regulatory T [Treg] cells) were higher in
the Ad-hMSC-administered group (Fig. 6a and b). For
our interest, recipient mice receiving rapamycin-treated
Ad-hMSCs showed a significantly decreased population
of Th17 cells in vivo compared to those receiving
untreated Ad-hMSCs (Fig. 6a and b). In summary,
administration of rapamycin-treated Ad-hMSCs had a
greater suppressive potential on the development of
aGVHD than did untreated Ad-hMSCs. The therapeutic
potential of rapamycin-treated Ad-hMSCs in an animal
model of aGVHD might be achieved by enhanced migra-
tion capacity and optimized immunoregulatory potential
of the cells. Furthermore, the autophagy-inducing proper-
ties of rapamycin could play a critical role in the
optimization of the use of Ad-hMSCs to prevent the de-
velopment of lethal aGVHD.
Discussion
We demonstrated that rapamycin, an mTOR inhibitor,
optimized the immunoregulatory properties of Ad-hMSCs
without affecting the panel of MSC markers evaluated
(positive for CD105, CD29, and CD44 and negative for
CD45 and HLA-DR). The enhanced immunoregulatory
potential induced by rapamycin was associated with
induction of autophagy in Ad-hMSCs and decreased
mTOR/Rictor/Raptor activity. Rapamycin treatment in
Ad-hMSCs also increased their migration potential sig-
nificantly. Ultimately, the administration of rapamycin-
treated Ad-hMSCs led to reduced mortality in aGVHD
recipients and attenuated the clinical severity of aGVHD.
One previous study demonstrated that systemic (intra-
peritoneal) treatment with rapamycin as an adjunct
Fig. 6 Analysis of T helper cell subsets in aGVHD mice administrated Ad-hMSCs or rapamycin-treated Ad-hMSCs. a Recipient BALB/c mice
received 5 × 106 bone marrow cells and 1 × 107 splenocytes from B6 mice after lethal irradiation with 800 cGy. On day 1 post BMT, recipient mice
received intravenous administration of Ad-hMSCs, rapamycin-treated Ad-hMSCs, or saline (control). Intracellular cytokine levels were determined
in splenic CD4+ T cells by confocal microscopy on day 12 after BMT. Histopathology and confocal microscopic images were obtained for each
mouse (n = 5), and representative images are shown. Bars represent the means ± SDs of data from five mice per group. **P < 0.01; ***P < 0.001.
The data are representative of at least three independent experiments. b The proportion of IFN-γ+ (mainly Th1), IL-4+ (mainly Th2), IL-17+ (mainly
Th17), and CD25+Foxp3+ (mainly Treg) among splenic CD4+ T cells were assessed ex vivo by intracellular fluorescence-activated cell sorting.
aGVHD acute graft-versus-host disease, Ad-hMSCs adipose tissue-derived human mesenchymal stem cells, BMT bone marrow transplantation
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therapy with MSC infusion in a mouse model of xeno-
genic GVHD resulted in a significantly decreased mortal-
ity rate, whereas there was no clinical benefit in MSC
alone-treated GVHD mice compared with the control
group [44], suggesting the beneficial effects of rapamycin
in the setting of MSC infusion. Based on the immunosup-
pressive and antitumor properties of rapamycin, it is being
increasingly used in GVHD prophylaxis [45] and steroid-
refractory GVHD [46]. Despite its significant advantages,
systemic administration of rapamycin showed specific
adverse events including reversible cytopenia that seems
to be dose-dependent and hyperlipidemia, occurring in
40 % and 61 % of organ transplant recipients [47–49],
raising concerns about its clinical uses in GVHD patients.
Since the first report that described the efficacy of MSCs
for the treatment of aGVHD [9], many publications have
presented a broad spectrum of response rate varying from
0 % [50] to 80 % [51]. In some cases, MSCs resulted in ac-
celerated graft rejection, even coadministered with cyclo-
sporine [52]. However, the clinical application of MSCs is
increasingly suggested as a third line treatment option in
the steroid-refractory aGVHD and may have a greater role
in the future [53], although this approach to prevent or
treat aGVHD is still far from routine. Thus, to optimize
the immunoregulatory properties of MSCs is now war-
ranted. Until now, there have been several attempts to
optimize the immunoregulatory actions of MSCs to
maximize their therapeutic potential, such as mRNA trans-
fection [54], adjunctive therapy [55], and selection of infu-
sion route [56]. Compared to these approaches, it is much
easier to adapt our work which showed that simple exposure
to a low concentration of rapamycin (nanomolar level) can
attain optimized immunoregulatory potential of Ad-hMSCs.
Acute GVHD is an immunological disorder that mainly
affects the skin, gastrointestinal tract, liver and lungs,
leading to tissue destruction. Classically, the interactions
between host APCs and donor T cells are reported to
activate the T helper 1 (Th1) cell-driven inflammatory
process, leading to development and progression of
aGVHD. However, emerging new data indicate that Th17
cells and Th17-associated cytokines play a central role in
the occurrence of aGVHD [57, 58]. IL-17 contributed to
the development of aGVHD in recipient mice by recruit-
ing or priming Th1 cells during the early stages of the
disease [59], reflecting a shift from Th1 to Th17 cells in
the physiopathology of aGVHD. In contrast to the Th17
subset, CD4+CD25+Foxp3+ Treg cells play a key role in
the control of alloreactive responses and in the mainten-
ance of immune tolerance after allogeneic BMT.
Treg cells that are critical in immune tolerance to al-
loantigen can prevent GVHD and show a suppressive
role in transplant tolerance [60], suggesting a thera-
peutic potential in GVHD prevention. Indeed, CD4
+CD25+ Treg cells expanded ex vivo have been shown
to delay or even prevent the severity of GVHD in an
animal model [61, 62]. Several preclinical studies have
demonstrated that CD4+CD25+Foxp3+ Treg cells play
critical roles for the induction and maintenance of
tolerance to alloantigens via a costimulatory pathway
[62, 63], suggesting the emergence of a new modality of
cellular therapy to prevent the development of lethal
GVHD. Furthermore, Sakaguchi et al. found that CD4
+CD25+ Treg cells can attenuate the rejection of allo-
geneic skin grafts [64]. In line with these findings, the
fraction of CD4+Foxp3+ Treg cells was relatively small in
human GVHD [65]. The deficiency of Treg cells may be
responsible for the consequent pathological differentiation
of effector CD4+ T cell subpopulations after BMT, in that
there could be a relative shift from Treg to Th1/Th17 line-
ages. In a phase I clinical trial, the incidence of grade 2–4
aGVHD in patients treated with ex-vivo expanded Treg
infusion was 43 % compared with 61 % in historical con-
trols who were identically treated [66].
Here, we have shown that rapamycin can induce au-
tophagy of Ad-hMSCs, while preserving the expression of
surface markers and multilineage differentiation potentials
of MSCs under in vitro conditions. That may underlie the
effective immunoregulatory property of Ad-hMSCs by
rapamycin treatment that was shown in a murine model
of aGVHD.
Prior to the clinical use of MSCs, it is important to
understand their biological roles fully. MSCs produce
immunosuppressive molecules and various growth fac-
tors that facilitate tissue repair [67]. Inflammatory me-
diators including cytokines, such as TNF-α and IFN-γ,
can stimulate the release of many growth factors by
MSCs, promoting tissue regeneration and repair [68].
Together with their reparative functions, MSCs retain
their immunosuppressive functions, e.g., by inducing
IL-10-secreting macrophages [69]. GVHD manifests as
a “cytokine storm”, the result of a BMT conditioning
regimen, activation of donor T cells by recipient APCs,
and the subsequent damage of host tissues by large
numbers of activated T cells (effector stage). As MSCs
produce growth factors and cytokines, issues with the
therapeutic use of MSCs in GVHD include minimization
of the production of proinflammatory and pro-angiogenic
molecules and optimization of MSC delivery to the target
tissues. In this study, the focus was on the optimization
strategy for MSCs with regard to their migration capacity
and the production of inflammatory molecules. In
addition, a strategy to optimize the potential of MSC-
based cell therapy to prevent lethal GVHD may reduce
the noted adverse events of the rapamycin than those
taken systemically. To summarize, our findings indicated
that rapamycin pretreatment of MSCs upregulated their
immunoregulatory properties and downregulated the pro-
duction of proinflammatory molecules involved in Th17
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differentiation, without affecting MSC characterization.
These effects were associated with autophagy induction,
and rapamycin treatment enhanced the migratory poten-
tial of MSCs. Encouragingly, rapamycin-treated MSCs
exerted more effective immunosuppressive properties in a
murine model of aGVHD. Therefore, autophagy induction
by rapamycin may represent an innovative strategy in the
optimization of the use of MSCs in other T-cell mediated
inflammatory disorders.
Conclusions
This study demonstrated that rapamycin treatment of Ad-
hMSCs can optimize their immunomodulatory properties
without affecting MSC characterization. The enhanced
immunoregulatory property of Ad-hMSCs by rapamycin
treatment is associated with inhibition of mTOR/Rictor/
Raptor signaling. The in vitro migration efficiency of
rapamycin-treated Ad-hMSCs towards CD4+ T cells is in-
creased compared with the untreated cells. The autophagy
induction property of rapamycin in Ad-hMSCs, at least
partially, contributes to the enhanced migration effi-
ciency. In a murine model of aGVHD, recipient mice
receiving rapamycin-treated Ad-hMSCs show less se-
vere clinical scores of aGVHD compared with those re-
ceiving untreated-Ad-hMSCs. The greater suppressive
potential of rapamycin-treated Ad-hMSCs shown in vivo
is associated with decreased Th17 subset. Our finding has
opened up a new way of optimization of MSCs against the
development of lethal aGVHD.
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